Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally. To date, over 142.1 million cases have been confirmed worldwide.
Vaccination rollouts have commenced in most countries in an attempt to arrest the spread of SARS-CoV-2. Antibody testing can help determine the magnitude of the pandemic and, at the same time, can be used for vaccine efficacy evaluation.
Studies have demonstrated that neutralizing antibody responses induced by messenger RNA (mRNA) vaccines such as Pfizer-BioNTech and Moderna correlate strongly with antibody measures by immunoassays such as enzyme-linked immunosorbent assay (ELISA).